| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03321643 Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03321643 Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
Trial terminated |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Primary completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Recruitment opened |
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Trial sites expanded: 0 -> 9 locations |
| 2026-06-09 | NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… |
Trial sites expanded: 192 -> 196 locations |
| 2026-06-06 | NCT06901531 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… |
Trial sites expanded: 238 -> 246 locations |
| 2026-06-06 | NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
date change Primary completion pushed: 2026-03 -> 2027-09 |
| 2026-06-06 | NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
date change Completion pushed: 2026-03 -> 2027-09 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Primary completion moved earlier: 2029-02-02 -> 2028-04-23 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Completion moved earlier: 2030-08-06 -> 2029-10-25 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Primary completion pushed: 2026-04-03 -> 2027-12-31 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Completion pushed: 2029-07-27 -> 2030-07-03 |
| 2026-06-05 | NCT04984837 Study of Lacutamab in Peripheral T-cell Lymphoma |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-05 | NCT04984837 Study of Lacutamab in Peripheral T-cell Lymphoma |
Enrollment reduced: 56 -> 49 participants |
| 2026-05-30 | NCT07043400 A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… |
Trial sites expanded: 86 -> 93 locations |
| 2026-05-30 | NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… |
Trial sites reduced: 50 -> 47 locations |
| 2026-05-30 | NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… |
Trial sites expanded: 187 -> 192 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07619313 AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07621484 HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07621497 FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Phase 3 | Recruiting |
| 2026-05-29 | NCT07613905 A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity… | Not Yet Recruiting | |
| 2026-05-26 | NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… | Phase 3 | Not Yet Recruiting |
| 2026-05-20 | NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… | Phase 2 | Not Yet Recruiting |
| 2026-05-19 | NCT07594964 To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as… | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07094893 | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type… | Colorectal Cancer | Not Yet Recruiting |
| Phase 3 | |||
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for… | Gastroesophageal-junction Cancer | Recruiting |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | Recruiting |
| NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch… | Resectable Colon Cancer | Recruiting |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma | Recruiting |
| NCT03801876 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Recruiting |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced… | Advanced Esophageal Adenocarcinoma | Recruiting |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab… | HER2-positive Gastric Cancer | Recruiting |
| NCT07113275 | A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by… | Rectal Cancer | Recruiting |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… | Gastric Cancer | Recruiting |
| NCT07043400 | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… | Metastatic Gastric Adenocarcinoma | Recruiting |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of… | Metastatic Colorectal Carcinoma | Recruiting |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… | Pancreatic Cancer | Recruiting |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Pancreatic Cancer | Recruiting |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… | Colorectal Neoplasms | Recruiting |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… | Colorectal Neoplasms | Recruiting |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Recruiting |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… | Colon Adenocarcinoma | Recruiting |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Rectal Cancer | Recruiting |
| NCT07340567 | Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal… | Colorectal Cancer | Not Yet Recruiting |
| NCT03399110 | XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) | Gastric Cancer | Active, Not Recruiting |
| NCT06206733 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or… | Gastroesophageal Junction Adenocarcinoma | Active, Not Recruiting |
| NCT04854668 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line… | Metastatic Colorectal Cancer | Active, Not Recruiting |
| NCT04340141 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable… | Pancreatic Adenosquamous Carcinoma | Active, Not Recruiting |
| NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant… | Colorectal Cancer Stage IV | Active, Not Recruiting |